The state of the art in treating patients with a dual diagnosis of chronic migraine and medication-overuse headache




Medication overuse headache, Chronic migraine, Treatment, Prophylaxis


Migraine is a common, highly prevalent genetic neurological disorder. Its most burdensome form is the chronic migraine, which is clinically defined by the presence of headache on ≥15 days/month for longer than three months, with eight or more typical migraine days. Medication-overuse headache (MOH) is a secondary headache disorder associated with the overuse of symptomatic headache medications on ≥10 days/month for longer than 3 months. Chronic migraine and medication-overuse headache often coexist and most chronic migraineurs have medication overuse headache. Despite that, general practitioners and health professionals do not know about MOH. This review aims at presenting insights, recent knowledge, and guidance regarding the approach and treatments for patients with a dual diagnosis of chronic migraine and medication-overuse headache.


Download data is not yet available.


Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38(1):1-211 Doi:10.1177/0333102417738202 DOI:

Harris L, L’Italien G, Kumar A, Seelam P, LaVallee C, Coric V and Lipton RB. Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States. Headache: The Journal of Head and Face Pain 2022; 62(4):473-481 Doi:10.1111/head.14289 DOI:

Schwedt TJ, Chiang C-C, Chong CD and Dodick DW. Functional MRI of migraine. The Lancet Neurology 2015; 14(1):81-91 Doi:10.1016/s1474-4422(14)70193-0 DOI:

Hovaguimian A and Roth J. Management of chronic migraine. Bmj 2022;e067670 Doi:10.1136/bmj-2021-067670 DOI:

Lin Y-K, Tsai C-L, Lin G-Y, Chou C-H and Yang F-C. Pathophysiology of Chronic Migraine: Insights from Recent Neuroimaging Research. Current Pain and Headache Reports 2022; 26(11):843-854 Doi:10.1007/s11916-022-01087-x DOI:

Oh SY, Kang JJ, Park HK, Cho SJ, Hong Y, Moon HS, . . . Chu MK. Clinical characteristics of medication‐overuse headache according to the class of acute medication: A cross‐sectional multicenter study. Headache: The Journal of Head and Face Pain 2022; 62(7):890-902 Doi:10.1111/head.14363 DOI:

Krymchantowski AV, Jevoux CC, Krymchantowski AG, Vivas RS and Silva-Néto R. Medication overuse headache: an overview of clinical aspects, mechanisms, and treatments. Expert Review of Neurotherapeutics 2020; 20(6):591-600 Doi:10.1080/14737175.2020.1770084 DOI:

Manack A, Buse DC, Serrano D, Turkel CC and Lipton RB. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011; 76(8):711-718 Doi:10.1212/WNL.0b013e31820d8af2 DOI:

Krymchantowski A, Jevoux C and Valença M. Medication-Overuse Headache: Differences between Daily and Near-Daily Headache Patients. Brain Sciences 2016; 6(3):30 Doi:10.3390/brainsci6030030 DOI:

Diener H-C, Kropp P, Dresler T, Evers S, Förderreuther S, Gaul C, . . . Lampl C. Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline. Neurological Research and Practice 2022; 4(1):37 Doi:10.1186/s42466-022-00200-0 DOI:

Find NL, Terlizzi R, Munksgaard SB, Bendtsen L, Tassorelli C, Nappi G, . . . Jensen R. Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. The Journal of Headache and Pain 2016;17(1):20 Doi:10.1186/s10194-016-0612-2 DOI:

Lisicki M, Flores JAC, Bordini CA, Goicochea MT and Peres MFP. Bridging the gaps of headache care for underserved populations: A medication overuse headache survey among international headache society members from Latin America. Cephalalgia Reports 2019; 2 Doi:10.1177/2515816318824076 DOI:

Viana M, De Icco R, Allena M, Sances G, Højland JR, Katsarava Z, . . . Stoppini A. Clinical Subtypes of Medication Overuse Headache – Findings From a Large Cohort. Headache: The Journal of Head and Face Pain 2019; 59(9):1481-1491 Doi:10.1111/head.13641 DOI:

Diener HC, Antonaci F, Braschinsky M, Evers S, Jensen R, Lainez M, . . . Petersen JA. European Academy of Neurology guideline on the management of medication‐overuse headache. European Journal of Neurology 2020; 27(7):1102-1116 Doi:10.1111/ene.14268 DOI:

Lake AE. Medication Overuse Headache: Biobehavioral Issues and Solutions. Headache: The Journal of Head and Face Pain 2006; 46(s3):S88-S97 Doi:10.1111/j.1526-4610.2006.00560.x DOI:

Scher AI and Bendtsen L. Patient-Centered Treatment of Chronic Migraine With Medication Overuse. Neurology 2022; 98(14):563-564 Doi:10.1212/wnl.0000000000200252 DOI:

Saper JR, Hamel RL and Lake AE. Medication Overuse Headache (MOH) is a Biobehavioural Disorder. Cephalalgia 2016; 25(7):545-546 Doi:10.1111/j.1468-2982.2005.00879.x DOI:

Carlsen LN, Westergaard ML, Bisgaard M, Schytz JB and Jensen RH. National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia 2017; 38(7):1316-1325 Doi:10.1177/0333102417736898 DOI:

Santiago MDS, Carvalho DdS, Gabbai AA, Pinto MMP, Moutran ARC and Villa TR. Amitriptyline and aerobic exercise or amitriptyline alone in the treatment of chronic migraine: a randomized comparative study. Arquivos de Neuro-Psiquiatria 2014; 72(11):851-855 Doi:10.1590/0004-282x20140148 DOI:

Tassorelli C, Jensen R, Allena M, De Icco R, Sances G, Katsarava Z, . . . Nappi G. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia 2014; 34(9):645-655 Doi:10.1177/0333102414521508 DOI:

Sun-Edelstein C and Rapoport AM. Update on the Pharmacological Treatment of Chronic Migraine. Current Pain and Headache Reports 2016; 20(1):6 Doi:10.1007/s11916-015-0533-9 DOI:

Kowacs F, Roesler CAdP, Piovesan ÉJ, Sarmento EM, Campos HCd, Maciel Jr JA, . . . Jurno ME. Consensus of the Brazilian Headache Society on the treatment of chronic migraine. Arquivos de Neuro-Psiquiatria 2019; 77(7):509-520 Doi:10.1590/0004-282x20190078 DOI:

Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, . . . Brin MF. OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program. Headache: The Journal of Head and Face Pain 2010; 50(6):921-936 Doi:10.1111/j.1526-4610.2010.01678.x DOI:

Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G and Nappi G. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. The Journal of Headache and Pain 2011; 12(4):427-433 Doi:10.1007/s10194-011-0339-z DOI:

Raffaelli B and Reuter U. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy. Neurotherapeutics 2018; 15(2):324-335 Doi:10.1007/s13311-018-0622-7 DOI:

Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, . . . Cady R. Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology 2020; 94(13):e1365-e1377 Doi:10.1212/wnl.0000000000009169 DOI:

Lipton RB and Silberstein SD. Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache: The Journal of Head and Face Pain 2015; 55:103-122 Doi:10.1111/head.12505_2 DOI:

Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, . . . Russo A. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. The Journal of Headache and Pain 2019; 20(1):92 Doi:10.1186/s10194-019-1038-4 DOI:

Diener H-C, Dodick DW, Goadsby PJ, Lipton RB, Olesen J and Silberstein SD. Chronic migraine—classification, characteristics and treatment. Nature Reviews Neurology 2012; 8(3): 162-171 Doi:10.1038/nrneurol.2012.13 DOI:

Krymchantowski AV, Krymchantowski AGF and Jevoux CdC. Medication-overuse headache. Retrospective comparison of preventive treatments. Arquivos de Neuro-Psiquiatria 2018; 76(10):668-673 Doi:10.1590/0004-282x20180097 DOI:

Krymchantowski AV, Tepper SJ, Jevoux C and Valença M. Medication-Overuse Headache: Protocols and Outcomes in 149 Consecutive Patients in a Tertiary Brazilian Headache Center. Headache: The Journal of Head and Face Pain 2017; 57(1):87-96 Doi:10.1111/head.12970 DOI:

Dozza ALCB and Krymchantowski AV. Adherence to migraine treatment does not depend on the number of prescribed medications. Arquivos de Neuro-Psiquiatria 2013; 71(3):171-173 Doi:10.1590/s0004-282x2013000300008 DOI:

Krymchantowski AV, da Cunha Jevoux C and Bigal ME. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. The Journal of Headache and Pain 2011; 13(1):53-59 Doi:10.1007/s10194-011-0395-4 DOI:

Krymchantowski AV and Bigal ME. Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach. Expert Review of Neurotherapeutics 2014; 6(3):283-289 Doi:10.1586/14737175.6.3.283 DOI:

Krymchantowski AV. Combining therapies for the treatment of migraine: is there a role? Expert Review of Neurotherapeutics 2014; 5(2):145-147 Doi:10.1586/14737175.5.2.145 DOI:

Ashina M, Terwindt GM, Al-Karagholi MA-M, de Boer I, Lee MJ, Hay DL, . . . Goadsby PJ. Migraine: disease characterisation, biomarkers, and precision medicine. The Lancet 2021; 397(10283):1496-1504 Doi:10.1016/s0140-6736(20)32162-0 DOI:

Pellesi L, Do TP, Ashina H, Ashina M and Burstein R. Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale? Headache: The Journal of Head and Face Pain 2020; 60(6):1056-1065 Doi:10.1111/head.13843 DOI:

Negro A, Curto M, Lionetto L and Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. The Journal of Headache and Pain 2016; 17(1): Doi:10.1186/s10194-016-0591-3 DOI:

Pensato U, Baraldi C, Favoni V, Mascarella D, Matteo E, Andrini G, . . . Cevoli S. Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. Cephalalgia 2022; 42(7):645-653 Doi:10.1177/03331024211067791 DOI:




How to Cite

Jevoux C, Krymchantowski A, Silva-Néto RP, Krymchantowski AG, Cotrik EM. The state of the art in treating patients with a dual diagnosis of chronic migraine and medication-overuse headache. Headache Med [Internet]. 2023 Sep. 30 [cited 2023 Dec. 6];14(3):153-60. Available from:




Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

<< < 1 2 3